RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.2 EUR | +0.79% |
|
+0.79% | +4.85% |
| May. 10 | Futures bullish; Mib restarts at 34,300 level | AN |
| May. 09 | Mib up, Nexi and Prysmian good after accounts | AN |
ETFs positioned on Recordati
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 306 M€ | +6.40% | - | |
| 0.00% | 39 M€ | +6.43% | - | |
| 0.00% | 105 M€ | +4.03% | - | |
| 0.00% | 17 M€ | +3.40% | - | |
| 0.00% | 34 M€ | +3.87% | - | |
| 0.00% | 234 M€ | +5.72% | - | |
| 0.00% | 54 M€ | +1.01% | - | |
| 0.00% | 8 M€ | +1.17% | - | |
| 0.00% | 1 M€ | 0.00% | - | |
| 0.00% | 29 M€ | 0.00% | - | |
| 0.00% | 146 M€ | -2.01% | - | |
| 0.00% | 25 M€ | -2.62% | - |
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-19
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
51.2
EUR
Average target price
52.24
EUR
Spread / Average Target
+2.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.85% | 11.46B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- REC Stock
- Funds and ETFs Recordati
